Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Lee, Young Jung ^a   Choi, Dong Young ^a   Choi, Im Seop ^a   Kim, Ki Ho ^b   Kim, Young Hee ^b   Kim, Hwan Mook ^c   Lee, Kiho ^c   Cho, Won Gil ^d   Jung, Jea Kyung ^a   Han, Sang Bae ^a   Han, Jin Yi ^a   Nam, Sang Yoon ^a   Yun, Young Won ^a   Jeong, Jae Hwang ^e   Oh, Ki Wan ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Bioland Ltd   (South Korea)

^c Gachon University College of Medicine   (South Korea)

^d Yonsei University Wonju College of Medicine   (South Korea)

^e Chungbuk Provincial College   (South Korea)

Author keywords

4 O methylhonokiol; Alzheimer's disease; Amyloid; Lipopolysaccharide; Magnolia officinalis; Memory impairment; Neuroinflammation

Indexed keywords

4 O METHYLHONOKIOL; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE; BETA SECRETASE 1; BRAIN PROTEIN; CYCLOOXYGENASE 2; GAMMA SECRETASE; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NOOTROPIC AGENT; PLANT EXTRACT; PROSTAGLANDIN E2; PROTEIN P50; REACTIVE OXYGEN METABOLITE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4-O-METHYLHONOKIOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); ASPARTIC PROTEINASE; BACE PROTEIN, RAT; BIPHENYL DERIVATIVE; CYTOKINE; LIGNAN; PEPTIDE FRAGMENT; SECRETASE;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BRAIN NUCLEUS; CELL ACTIVATION; CELL NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY DISORDER; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; TRANSCRIPTION REGULATION; ANALYSIS OF VARIANCE; ANIMAL; AVOIDANCE BEHAVIOR; BRAIN; CELL LINE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; GEL MOBILITY SHIFT ASSAY; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MAZE TEST; METABOLISM; NICK END LABELING; PATHOLOGY;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPARTIC ACID ENDOPEPTIDASES; ASTROCYTES; AVOIDANCE LEARNING; BIPHENYL COMPOUNDS; BRAIN; CELL LINE, TRANSFORMED; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; IN SITU NICK-END LABELING; INFLAMMATION; LIGNANS; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED ICR; MICROGLIA; NF-KAPPA B; NITRIC OXIDE; PEPTIDE FRAGMENTS;

EID: 84862776502     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-35     Document Type: Article

References (97)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403. 10.1016/S0140-6736(06)69113-7, 16876668.
2. Ferri CP, Sousa R, Albanese E, Ribeiro WS, Honyashiki M. World Alzheimer Report 2009-Executive Summary. 2009, 1-22. London: Alzheimer's Disease International, Prince M, Jackson J.
3. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 2004, 3:445-464. 10.1016/j.arr.2004.08.001, 15541711.
4. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996, 47:425-432.
5. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 2004, 295:245-257. 10.1016/j.yexcr.2004.01.002, 15051507.
6. Orellana DI, Quintanilla RA, Gonzalez-Billault C, Maccioni RB. Role of the JAKs/STATs pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons. Neurotox Res 2005, 8:295-304. 10.1007/BF03033983, 16371324.
7. Orellana DI, Quintanilla RA, Maccioni RB. Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by CDK5 kinase. Biochim Biophys Acta 2007, 1773:254-263. 10.1016/j.bbamcr.2006.10.010, 17150266.
8. Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A. Neuroinflammation in Alzheimer's disease and prion disease. Glia 2002, 40:232-239. 10.1002/glia.10146, 12379910.
9. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:741-749. 10.1016/S0278-5846(03)00124-6, 12921904.
10. Guo JT, Yu J, Grass D, de Beer FC, Kindy MS. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 2002, 22:5900-5909.
11. Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad B, Bogdanovi. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol 2000, 165:12-26. 10.1006/exnr.2000.7448, 10964481.
12. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992, 89:10075-10078. 10.1073/pnas.89.21.10075, 50280, 1359534.
13. Hirose Y, Imai Y, Nakajima K, Takemoto N, Toya S, Kohsaka S. Glial conditioned medium alters the expression of amyloid precursor protein in SH-SY5Y neuroblastoma cells. Biochem Biophys Res Commun 1994, 198:504-509. 10.1006/bbrc.1994.1074, 8297361.
14. Blasko I, Marx F, Steiner E, Hartmann T, Grubeck-Loebenstein B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999, 13:63-68.
15. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003, 23:9796-9804.
16. Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci 2001, 17:157-170. 10.1385/JMN:17:2:157, 11816789.
17. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005, 25:8807-8814. 10.1523/JNEUROSCI.1521-05.2005, 16177050.
18. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 2006, 281:16419-16427. 10.1074/jbc.M600617200, 16624814.
19. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992, 42:447-449.
20. Shaw KN, Commins S, O'Mara SM. Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. Behav Brain Res 2001, 124:47-54. 10.1016/S0166-4328(01)00232-7, 11423165.
21. Sparkman NL, Martin LA, Calvert WS, Boehm GW. Effects of intraperitoneal lipopolysaccharide on Morris maze performance in year-old and 2-month-old female C57BL/6J mice. Behav Brain Res 2005, 159:145-151. 10.1016/j.bbr.2004.10.011, 15795008.
22. Parnet P, Kelley KW, Bluthe RM, Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. J Neuroimmunol 2002, 125:5-14. 10.1016/S0165-5728(02)00022-X, 11960635.
23. Zhang F, Qian L, Flood PM, Shi JS, Hong JS, Gao HM. Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther 2010, 333:822-833. 10.1124/jpet.110.165829, 2879929, 20190013.
24. Hang CH, Shi JX, Tian J, Li JS, Wu W, Yin HX. Effect of systemic LPS injection on cortical NF-kappaB activity and inflammatory response following traumatic brain injury in rats. Brain Res 2004, 1026:23-32. 10.1016/j.brainres.2004.07.090, 15476694.
25. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010, 33:1539-1556. 10.1007/s12272-010-1006-7, 21052932.
26. Wang L-Y, Niu Z-Z, Hu B-X, Wu J-M, Jiang X, Hu X-F, Huang W-H, Ouyang J, Yu L, Qiu X-Z. Long-term intraperitoneal injection of lipopolysaccharide induces high expression of Id2 in the brain of mice. Mol Biol Rep 2011, 38:4193-4196. 10.1007/s11033-010-0540-1, 21110107.
27. Lee YK, Yuk DY, Lee JW, Lee SY, Ha TY, Oh KW, Yun YP, Hong JT. (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res 2008, 1250:164-174.
28. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008, 5:37. 10.1186/1742-2094-5-37, 2556656, 18759972.
29. Kuribara H, Kishi E, Hattori N, Okada M, Maruyama Y. The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. J Pharm Pharmacol 2000, 52:1425-1429.
30. Li Y, Xu C, Zhang Q, Liu JY, Tan RX. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J Ethnopharmacol 2005, 98:329-333. 10.1016/j.jep.2005.01.020, 15814268.
31. Ock J, Han HS, Hong SH, Lee SY, Han YM, Kwon BM, Suk K. Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br J Pharmacol 2010, 159:1646-1662. 10.1111/j.1476-5381.2010.00659.x, 2925488, 20397299.
32. Lin YR, Chen HH, Ko CH, Chan MH. Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sci 2007, 81:1071-1078. 10.1016/j.lfs.2007.08.014, 17826802.
33. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol 2007, 179:753-763.
34. Chen YH, Lin SJ, Chen YL, Liu PL, Chen JW. Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules. Cardiovasc Hematol Disord Drug Targets 2006, 6:279-304.
35. Zhou HY, Shin EM, Guo LY, Youn UJ, Bae K, Kang SS, Zou LB, Kim YS. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Eur J Pharmacol 2008, 586:340-349. 10.1016/j.ejphar.2008.02.044, 18378223.
36. Lin YR, Chen HH, Ko CH, Chan MH. Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol 2006, 537:64-69. 10.1016/j.ejphar.2006.03.035, 16631734.
37. Bajpai VK, Yoon JI, Kang SC. Antioxidant and antidermatophytic activities of essential oil and extracts of Magnolia liliflora Desr. Food Chem Toxicol 2009, 47:2606-2612. 10.1016/j.fct.2009.07.025, 19635519.
38. Dikalov S, Losik T, Arbiser JL. Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol 2008, 76:589-596. 10.1016/j.bcp.2008.06.012, 2575413, 18640101.
39. Chen YH, Lin FY, Liu PL, Huang YT, Chiu JH, Chang YC, Man KM, Hong CY, Ho YY, Lai MT. Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats. Arch Pharm Res 2009, 32:221-228. 10.1007/s12272-009-1139-8, 19280152.
40. Oh JH, Kang LL, Ban JO, Kim YH, Kim KH, Han SB, Hong JT. Anti-inflammatory effect of 4-O-methylhonokiol, a novel compound isolated from Magnolia officinalis through inhibition of NF-kappaB. Chem Biol Interact 2009, 180:506-514. 10.1016/j.cbi.2009.03.014, 19539808.
41. Lee YK, Choi IS, Kim YH, Kim KH, Nam SY, Yun YW, Lee MS, Oh KW, Hong JT. Neurite Outgrowth Effect of 4-O-methylhonokiol by Induction of Neurotrophic Factors Through ERK Activation. Neurochem Res 2009, 34:2251-2260. 10.1007/s11064-009-0024-7, 19557513.
42. Lee JW, Lee YK, Ban JO, Ha TY, Yun YP, Han SB, Oh KW, Hong JT. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 2009, 139:1987-1993. 10.3945/jn.109.109785, 19656855.
43. Lee JW, Lee YK, Lee BJ, Nam SY, Lee SI, Kim YH, Kim KH, Oh KW, Hong JT. Inhibitory effect of ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on memory impairment and neuronal toxicity induced by beta-amyloid. Pharmacol Biochem Behav 2010, 95:31-40. 10.1016/j.pbb.2009.12.003, 20004682.
44. Lee YJ, Choi IS, Park MH, Lee YM, Song JK, Kim YH, Kim KH, Hwang DY, Jeong JH, Yun YP, et al. 4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway. Free Radic Biol Med 2011, 50:66-77. 10.1016/j.freeradbiomed.2010.10.698, 20974250.
45. Lee YK, Yuk DY, Kim TI, Kim YH, Kim KT, Kim KH, Lee BJ, Nam SY, Hong JT. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. J Nat Med 2009, 63:274-282. 10.1007/s11418-009-0330-z, 2690856, 19343477.
46. Rao KV, Davis TL. Constituents of Magnolia grandiflora i: mono-O-methylhonokiol. Planta Med 1982, 45:57-59. 10.1055/s-2007-971246, 17396785.
47. Yahara S, Nishiyori T, Kohda T, Nohara T, Nishioka I. Isolation and Characterization of Phenolic Compounds from Magnoliae Cortex Produced in China. Chemistry Pharmacology Bulletin 1991, 39:2024-2036.
48. Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, Jung JK, Kim YH, Kim KH, Oh KW, Hong JT. 4-O-methylhonokiol attenuated beta-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase. J Nutr Biochem 2011, 22:476-486. 10.1016/j.jnutbio.2010.04.002, 20688501.
49. Erickson MA, Banks WA. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: Multiplex quantification with path analysis. Brain Behav Immun 2011, 25:1637-1648. 10.1016/j.bbi.2011.06.006, 21704698.
50. Czapski GA, Gajkowska B, Strosznajder JB. Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus. Brain Res 2010, 1356:85-94.
51. Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, Shah GN, Price TO, Fleegal-Demotta MA, Butterfiled DA, Banks WA. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 2009, 23:507-517. 10.1016/j.bbi.2009.01.017, 2783557, 19486646.
52. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60. 10.1016/0165-0270(84)90007-4, 6471907.
53. Park KS, Lee RD, Kang SK, Han SY, Park KL, Yang KH, Song YS, Park HJ, Lee YM, Yun YP, et al. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway. Exp Cell Res 2004, 297:424-433. 10.1016/j.yexcr.2004.03.034, 15212945.
54. Lee SM, Nguyen TH, Park MH, Kim KS, Cho KJ, Moon DC, Kim HY, Yoon DY, Hong JT. EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun 2004, 320:1087-1095. 10.1016/j.bbrc.2004.06.060, 15249201.
55. Szczepanik AM, Ringheim GE. IL-10 and glucocorticoids inhibit Abeta(1-42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis 2003, 5:105-117.
56. Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 2006, 1:1591-1595. 10.1038/nprot.2006.277, 17406451.
57. Nguyen HN, Lee MS, Hwang DY, Kim YK, Yoon do Y, Lee JW, Yun YP, Lee MK, Oh KW, Hong JT. Mutant presenilin 2 increased oxidative stress and p53 expression in neuronal cells. Biochem Biophys Res Commun 2007, 357:174-180. 10.1016/j.bbrc.2007.03.119, 17418105.
58. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421. 10.1016/S0197-4580(00)00124-X, 10858586.
59. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 2002, 11:257-274. 10.1006/nbdi.2002.0538, 12505419.
60. Veerhuis R. Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 2011, 8:34-58. 10.2174/156720511794604589, 21143154.
61. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001, 7:548-554. 10.1016/S1471-4914(01)02173-6, 11733217.
62. Morley JE, Farr SA, Kumar VB, Banks WA. Alzheimer's disease through the eye of a mouse. Acceptance lecture for the 2001 Gayle A. Olson and Richard D. Olson prize. Peptides 2002, 23:589-599. 10.1016/S0196-9781(01)00630-1, 11836012.
63. Mouton PR, Kelley-Bell B, Tweedie D, Spangler EL, Perez E, Carlson OD, Short RG, Decabo R, Chang J, Ingram DK, et al. The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons. Neurobiol Aging 2012, 33:423 e427-436.
64. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003, 14:133-145. 10.1016/S0969-9961(03)00069-X, 13678674.
65. Michelucci A, Heurtaux T, Grandbarbe L, Morga E, Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol 2009, 210:3-12. 10.1016/j.jneuroim.2009.02.003, 19269040.
66. Heneka MT, Kummer MP, Weggen S, Bulic B, Multhaup G, Munter L, Hull M, Pflanzner T, Pietrzik CU. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Alzheimer Res 2011, 8:115-131.
67. Gunasingh MJ, Philip JE, Ashok BS, Kirubagaran R, Jebaraj WC, Davis GD, Vignesh S, Dhandayuthapani S, Jayakumar R. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism. Life Sci 2008, 83:96-102. 10.1016/j.lfs.2008.05.011, 18590917.
68. Schubert D, Soucek T, Blouw B. The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide. Eur J Neurosci 2009, 29:1323-1334. 10.1111/j.1460-9568.2009.06712.x, 2752839, 19519624.
69. Cho HJ, Kim SK, Jin SM, Hwang EM, Kim YS, Huh K, Mook-Jung I. IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia 2007, 55:253-262. 10.1002/glia.20451, 17091494.
70. Hartlage-Rubsamen M, Zeitschel U, Apelt J, Gartner U, Franke H, Stahl T, Gunther A, Schliebs R, Penkowa M, Bigl V, Rossner S. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 2003, 41:169-179. 10.1002/glia.10178, 12509807.
71. Sheng B, Gong K, Niu Y, Liu L, Yan Y, Lu G, Zhang L, Hu M, Zhao N, Zhang X, et al. Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer's disease. Free Radic Biol Med 2009, 46:1362-1375. 10.1016/j.freeradbiomed.2009.02.018, 19264123.
72. Guglielmotto M, Tamagno E, Danni O. Oxidative stress and hypoxia contribute to Alzheimer's disease pathogenesis: two sides of the same coin. ScientificWorldJournal 2009, 9:781-791.
73. Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW, Hong JT. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 2009, 47:1601-1610. 10.1016/j.freeradbiomed.2009.09.008, 19766184.
74. Massaad CA, Washington TM, Pautler RG, Klann E. Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009, 106:13576-13581. 10.1073/pnas.0902714106, 2726352, 19666610.
75. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman RW. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 2007, 28:213-225. 10.1016/j.neurobiolaging.2005.12.014, 16448723.
76. Ju TC, Chen SD, Liu CC, Yang DI. Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free Radic Biol Med 2005, 38:938-949. 10.1016/j.freeradbiomed.2004.12.019, 15749390.
77. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA. Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 2005, 26(Suppl 1):133-136.
78. Garcia-Matas S, de Vera N, Aznar AO, Marimon JM, Adell A, Planas AM, Cristofol R, Sanfeliu C. In vitro and in vivo activation of astrocytes by amyloid-beta is potentiated by pro-oxidant agents. J Alzheimers Dis 2010, 20:229-245.
79. Parachikova A, Vasilevko V, Cribbs DH, LaFerla FM, Green KN. Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis 2010, 21:527-542.
80. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414:212-216. 10.1038/35102591, 11700559.
81. Vane J. The mechanism of action of anti-inflammatory drugs. Int J Clin Pract Suppl 2003, 135:2.
82. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA 2006, 103:443-448. 10.1073/pnas.0503839103, 1326151, 16407166.
83. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology 2005, 30:1111-1120. 10.1038/sj.npp.1300668, 15688088.
84. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, Gonzalez-DeWhitt PA, Gelfanova V, Hale JE, May PC, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003, 302:1215-1217. 10.1126/science.1090154, 14615541.
85. Wilkinson BL, Cramer PE, Varvel NH, Reed-Geaghan E, Jiang Q, Szabo A, Herrup K, Lamb BT, Landreth GE. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. Neurobiol Aging 2012, 33:197 e121-132.
86. von Arnim CA, Spoelgen R, Peltan ID, Deng M, Courchesne S, Koker M, Matsui T, Kowa H, Lichtenthaler SF, Irizarry MC, Hyman BT. GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. J Neurosci 2006, 26:9913-9922. 10.1523/JNEUROSCI.2290-06.2006, 17005855.
87. Rossner S, Sastre M, Bourne K, Lichtenthaler SF. Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease. Prog Neurobiol 2006, 79:95-111. 10.1016/j.pneurobio.2006.06.001, 16904810.
88. Rossner S. New players in old amyloid precursor protein-processing pathways. Int J Dev Neurosci 2004, 22:467-474. 10.1016/j.ijdevneu.2004.07.004, 15465276.
89. Hsieh HL, Wang HH, Wu CY, Yang CM. Reactive Oxygen Species-Dependent c-Fos/Activator Protein 1 Induction Upregulates Heme Oxygenase-1 Expression by Bradykinin in Brain Astrocytes. Antioxid Redox Signal 2010, 13:1829-1844. 10.1089/ars.2009.2957, 20486760.
90. Marcus JS, Karackattu SL, Fleegal MA, Sumners C. Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-kappaB. Glia 2003, 41:152-160. 10.1002/glia.10168, 12509805.
91. Grilli M, Ribola M, Alberici A, Valerio A, Memo M, Spano P. Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J Biol Chem 1995, 270:26774-26777. 10.1074/jbc.270.45.26774, 7592914.
92. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007, 85:1194-1204. 10.1002/jnr.21252, 17385716.
93. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003, 112:440-449. 166298, 12897211.
94. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM, Pratico D. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 2004, 165:2197-2206. 10.1016/S0002-9440(10)63269-5, 1618710, 15579461.
95. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 2007, 8:54. 10.1186/1471-2202-8-54, 1948891, 17650315.
96. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C, Arendash GW. Sorafenib inhibits nuclear factor kappa B, decreases inducible nitric oxide synthase and cyclooxygenase-2 expression, and restores working memory in APPswe mice. Neuroscience 2009, 162:1220-1231. 10.1016/j.neuroscience.2009.05.019, 19447162.
97. Pan XD, Chen XC, Zhu YG, Chen LM, Zhang J, Huang TW, Ye QY, Huang HP. Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 2009, 57:1227-1238. 10.1002/glia.20844, 19170180.